Exelixis Announces January 11 Webcast of Presentation at the J.P. Morgan 30th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (EXEL) today announced that Michael M. Morrissey, Ph.D., the companys president and chief executive officer, will present at the J.P. Morgan 30th Annual Healthcare Conference at 6:30 p.m. EST / 3:30 p.m. PST on Wednesday, January 11, 2012, in San Francisco. During the presentation, Dr. Morrissey will review the development plans and priorities for cabozantinib in 2012. He will also highlight potential future data presentations, discuss the companys corporate strategy and financial outlook, and provide a general business update.
The presentation will be webcast and may be accessed in the Event Calendar page under Investors at www.exelixis.com.
Exelixis, Inc. is a biotechnology company committed to developing small molecule therapeutics for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on cabozantinib, its most advanced solely-owned product candidate, in order to maximize the therapeutic and commercial potential of this compound. Exelixis believes cabozantinib has the potential to be a high-quality, differentiated pharmaceutical product that can make a meaningful difference in the lives of patients. Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs. For more information, please visit the company's web site at www.exelixis.com.
Charles Butler, 650-837-7277
Investor Relations and
Source: Exelixis, Inc.Copyright Business Wire 2011